8-methoxy-N-phenylpyrimido[4,5-b][1,4]benzoxazepin-4-amine | 833448-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 8-methoxy-N-phenylpyrimido[4,5-b][1,4]benzoxazepin-4-amine
• CAS: 833448-86-5
• 化学式: C₁₈H₁₄N₄O₂
• 分子量: 318.335
• InChiKey: DMFLYZUQWWGWOE-UHFFFAOYSA-N

物化性质

• 沸点：
  530.0±50.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  8-methoxy-N-phenylpyrimido[4,5-b][1,4]benzoxazepin-4-amine 在 锂硼氢 作用下， 以 四氢呋喃 为溶剂， 生成 (8-Methoxy-10,11-dihydro-5-oxa-2,4,11-triaza-dibenzo[a,d]cyclohepten-1-yl)-phenyl-amine
  参考文献：
  名称：

  Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors

  摘要：

  A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.018
• 作为产物：
  描述：

  2-羟基-5-甲氧基苯甲醛 、 6-氯-N4-苯基-4,5-嘧啶二胺 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 8-methoxy-N-phenylpyrimido[4,5-b][1,4]benzoxazepin-4-amine
  参考文献：
  名称：

  Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors

  摘要：

  A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.018

文献信息

• [EN] EGFR TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE EGFR
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005009384A2

  公开（公告）日：2005-02-03

  The invention encompasses compounds that inhibit, modulate, or regulate kinases, compositions that contain kinase inhibiting compounds, and methods of treating kinase-dependent diseases and conditions in subjects in need of such treatment. Also, the invention encompasses methods of making compounds that inhibit, modulate or regulate kinases.
• Microwave-assisted three component one-pot synthesis of pyrimido-oxazepines
  作者：Colleen Hudson、V. Srinivasa Murthy、Kimberly G. Estep、Gary Gustafson

  DOI：10.1016/j.tetlet.2006.12.058

  日期：2007.2

  A synthetic approach toward pyrimido-oxazepine analogs was developed through the use of microwave heating. Certain analogs can be made in one step, which make this a valuable tool in the investigation of this therapeutically relevant scaffold. (c) 2007 Elsevier Ltd. All rights reserved.
• Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors
  作者：Leon Smith、Evgueni L. Piatnitski、Alexander S. Kiselyov、Xiaohu Ouyang、Xiaoling Chen、Sabina Burdzovic-Wizemann、Yongjiang Xu、Ying Wang、Robin L. Rosler、Sheetal N. Patel、Hui-Hsien Chiang、Daniel L. Milligan、John Columbus、Wai C. Wong、Jacqueline F. Doody、Yaron R. Hadari

  DOI：10.1016/j.bmcl.2005.12.018

  日期：2006.3

  A novel class of pyrimido[4,5-b]-1,4-benzoxazepines is described as inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase. Two compounds display potent EGFR inhibitory activity of less than 1 mu M in cellular phosphorylation assays (IC50 0.47-0.69 mu M) and are highly selective against a small kinase panel. Such compounds demonstrate anti-EGFR activity within a class that is different from any known EGFR inhibitor scaffolds. They also provide a basis for the design of kinase inhibitors with the desired selectivity profile. (C) 2005 Elsevier Ltd. All rights reserved.